Søren Weis Dahl
Chief Executive Officer at Deck Therapeutics, Inc.
Søren Weis Dahl active positions
| Companies | Position | Start | End |
|---|---|---|---|
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Director/Board Member | 31/12/2013 | - |
| Chief Executive Officer | 31/12/2013 | - |
Career history of Søren Weis Dahl
Former positions of Søren Weis Dahl
| Companies | Position | Start | End |
|---|---|---|---|
| PILA PHARMA AB | Director/Board Member | 29/05/2023 | 31/03/2024 |
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Chief Executive Officer | 31/03/2015 | 31/12/2018 |
Training of Søren Weis Dahl
| Technical University of Denmark | Graduate Degree |
| Copenhagen Business School | Masters Business Admin |
Statistics
International
| Denmark | 3 |
| Norway | 2 |
| United States | 2 |
Operational
| Chief Executive Officer | 2 |
| Director/Board Member | 2 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PILA PHARMA AB | Health Technology |
| Private companies | 2 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Søren Weis Dahl
- Experience
